股票/基金 实时行情 股吧

简称:昭衍新药 代码:603127


会计年度:2021-12-31收入分布
项目名称主营业务收入主营业务成本主营业务毛利毛利率
合计1,516,680,031.67777,557,988.82739,122,042.8548.73
临床服务及其他30,513,582.9319,539,126.2010,974,456.7335.97
实验模型供应3,551,078.621,910,722.061,640,356.5646.19
药物非临床研究服务1,482,615,370.12756,108,140.56726,507,229.5649.00

会计年度:2020-12-31 
项目名称主营业务收入主营业务成本主营业务毛利毛利率
合计1,075,904,934.98523,092,081.71552,812,853.2751.38
临床服务及其他20,976,469.1310,531,442.5010,445,026.6349.79
实验动物供应2,169,464.401,551,375.91618,088.4928.49
药物临床前研究服务1,052,759,001.45511,009,263.30541,749,738.1551.46

会计年度:2020-06-30 
项目名称主营业务收入主营业务成本主营业务毛利毛利率
非临床服务393,924,517.27196,804,368.42197,120,148.8550.04
分部间抵销-846,603.77-2,055,486.731,208,882.96-142.79
合计397,354,998.31198,024,267.05199,330,731.2650.16
临床服务3,461,006.412,716,028.07744,978.3421.52
实验动物及其他816,078.40559,357.29256,721.1131.46

会计年度:2019-12-31 
项目名称主营业务收入主营业务成本主营业务毛利毛利率
合计639,379,338.02302,817,779.12336,561,558.9052.64
临床服务2,754,030.241,595,348.171,158,682.0742.07
其他(补充)1,349,025.221,702,239.53-353,214.31-26.18
实验动物及附属产品销售业务4,281,820.802,921,836.051,359,984.7531.76
药物警戒服务2,152,872.042,995,029.17-842,157.13-39.12
药物临床前研究服务628,841,589.72293,603,326.20335,238,263.5253.31

会计年度:2019-06-30 
项目名称主营业务收入主营业务成本主营业务毛利毛利率
分部间抵销---2,244,379.482,244,379.48--
合计200,863,882.7998,614,802.96102,249,079.8350.90
技术服务收入195,597,900.7996,615,458.9298,982,441.8750.61
平衡项目3,101,662.532,744,938.01356,724.5211.50
其他(补充)742,288.67895,331.15-153,042.48-20.62
实验动物生产与销售1,422,030.80603,454.36818,576.4457.56

    1/2 转到